He says this has gone on for around two years, meaning many people are taking a drug at scale before it has even reached the market.
Recap by typeshit. Post by @StevenBartlett on X.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
Adding an experimental hormone mimic to tirzepatide pushed body mass reduction as high as 23.3% in a Lilly clinical trial, per NewsBytes.
Novo also presented liver fat data from STEP-UP and an Ozempic vs Mounjaro heart risk analysis, and paid $300 million upfront for Hengrui's HRS-1596.
Loading…